| durvalumab based treatment | nivolumab based treatment | pembrolizumab based treatment | Immune checkpoint association |
| durvalumab alone | nivolumab alone | pembrolizumab alone | durvalumab plus tremelimumab |
mHNSCC - 2nd line (L2) | | | | |
mHNSCC - L2 - all population 4 | | | | |
mHNSCC - L2 - PDL1 negative 2 | | | | |
mHNSCC - L2 - PDL1 positive 1 | | | | |